International Conference on Antiviral Research (ICAR2024) (May 20-24, 2024 Gold Coast, Australia) May 20 - May 24, 2024 Travatrelvir, an Inhibitor of SARS-CoV-2 Main Protease now in Phase 1 Clinical Trials: in vitro Drug Resistance Compared to Nirmatrelvir 854.8 KB
Travatrelvir, an Inhibitor of SARS-CoV-2 Main Protease now in Phase 1 Clinical Trials: in vitro Drug Resistance Compared to Nirmatrelvir 854.8 KB
